CureVac (CVAC) has released an update.
CureVac N.V., a biopharmaceutical company, has reported a net loss of €70,553 thousand for the first quarter of 2024, deepening from the €57,419 thousand loss in the same period last year. The company saw an increase in revenue to €12,373 thousand, but this was outstripped by rising costs, leading to a larger operating loss. CureVac’s financial position shows a decrease in total assets from €788,249 thousand at the end of 2023 to €690,433 thousand as of March 31, 2024.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
